Shopping Cart
Remove All
Your shopping cart is currently empty
AKT-IN-17 is an orally administered AKt inhibitor. It induces apoptosis (Apoptosis) by inhibiting AKt within A549 cells and is applicable to non-small cell lung cancer research.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Backorder | Backorder | |
| 50 mg | Inquiry | Backorder | Backorder |
| Description | AKT-IN-17 is an orally administered AKt inhibitor. It induces apoptosis (Apoptosis) by inhibiting AKt within A549 cells and is applicable to non-small cell lung cancer research. |
| In vitro | AKT-IN-17 exhibits cytotoxic activity against A549 cells at a concentration of 176.32 μM, while it shows no effect on normal L929 cells, with an IC 50 of 176.32 μM. When applied at concentrations of 44.06, 88.12, and 176.23 μM for 24 hours, AKT-IN-17 inhibits AKt within A549 cells with an IC 50 of 105.88 μM. Additionally, at 176.23 μM for 24 hours, AKT-IN-17 induces early apoptosis in A549 cells by 3.26% and late apoptosis by 1.76%. |
| Formula | C21H21ClN4O2S |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.